Koffiekamer « Terug naar discussie overzicht

Swingtrades in reguliere bedrijven

5.451 Posts, Pagina: « 1 2 3 4 5 6 ... 36 37 38 39 40 41 42 43 44 45 46 ... 269 270 271 272 273 » | Laatste

Omlaag ↓

[verwijderd] 24 mei 2010 16:52

RPRX .61
verwacht wel verwatering na fda nieuws

Proellex®, a new chemical entity that acts as a selective blocker of the progesterone receptor, is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis, subject to the current FDA clinical hold on the Proellex® clinical trials; however, we have recently filed for a limited removal of the clinical hold in order to commence certain clinical trials of Proellex® at a 12 mg or lower dose level. On April 29, 2010 a teleconference was held with the FDA to review the clinical hold status of Proellex®. During the teleconference the FDA noted that it felt that not all of their concerns were fully answered but opined that if the Company was willing to modify the trial from a parallel design to an escalating dose design the FDA would consider lifting the full clinical hold and place Proellex® on partial clinical hold to allow the low dose trial to be conducted. The Company agreed to modify the protocol and submitted the new design to the Agency on April 30, 2010.

Bijlage:

[verwijderd] 24 mei 2010 17:04

CRXX 1.44
(geen trendlijnen)

Bijlage:

[verwijderd] 24 mei 2010 19:52

Overall market wel erg belangrijk nu
aantal korte scalps.

Veel mooie setups nu, maar dna moet vrijdag candle het wel houden

[verwijderd] 24 mei 2010 20:25

meer CXM toegevoegd
orders .44 en .45 niet gevuld
.48 extra bijgekocht
nog steeds 510k fda play (wound dressing)

[verwijderd] 25 mei 2010 10:13

Dieprode futures
ook met swings erg oppassen

SPX retest 1000 ? en INDU 9500 ?
(9850 zone zou fijn zijn om te houden maar anders retest 9500)

[verwijderd] 25 mei 2010 16:33

CPST groen vandaag
1.05 teruggekocht

50-55% cash nu
aantal zijn vlak zoals PKTX (pinkie) , MYFT (pinkie)

IMMU kijken of ie hier bounced rond 3,10 of dat ie 2,90 kan retest, verwavht nog steeeds leuke stijging ruchting 16-19juni

[verwijderd] 25 mei 2010 16:59

NIV 2.12 Great china growth stock target 3$ first soon
NIV ticker = NVIS company

great earnings numbers and outlook

-- Net income increased 121% to $5.3 million
-- Diluted EPS increased to $0.13 from $0.06
-- Company offers guidance for balance of 2010

Guidance for 2010 business operations

The Company expects 20-30% growth in fiscal 2010 for its traditional audio and visual products compared with fiscal 2009, with gross and net profit margin maintained at approximately 22-25% and 10-12%, respectively. The mobile phone business is a new product line for the Company and is expected to contribute $60-90 million of revenue in 2010 and with gross and net profit margins ranging from approximately 10-18% and 5-9%, respectively. The Company hopes to further enhance its margins by incorporating increased product functionality and enhanced product design into its recently acquired mobile phone manufacturing operations.

Overall, the Company anticipates that it will generate $280-330 million of revenue, with gross and net margins estimated to range between 19-21% and 7-10%, respectively, in 2010.

weekly chart, strong support here

4k gekocht voor swing, target 3$

Bijlage:

[verwijderd] 25 mei 2010 17:17

IMMU

BRIEF-Immunomedics receives second milestone payment from Nycomed
May 25 (Reuters) - Immunomedics Inc <IMMU.O>:
* Receives second milestone payment from nycomed
* Says can potentially get up to $580 million from nycomed on certain clinical,
regulatory, and sales-based milestones
* Says received $4.3 million in proceeds from the liquidation of one of the
auction rate securities
* Says receipt of $5 million from nycomed for reaching a clinical milestone

[verwijderd] 25 mei 2010 17:24

quote:
crackedtooth schreef:
CPST groen vandaag
1.05 teruggekocht

50-55% cash nu
aantal zijn vlak zoals PKTX (pinkie) , MYFT (pinkie)

IMMU kijken of ie hier bounced rond 3,10 of dat ie 2,90 kan retest, verwavht nog steeeds leuke stijging ruchting 16-19juni

Knap gedaan, alleen CPST was gister tot het laatste uur van de sessie steeds boven de $1,10, bij welke broker krijg jij zoveel korting?

[verwijderd] 25 mei 2010 17:28

Flatus: CPST vandaag gekocht 1.05, had je zelfs 2x de kans toe wanneer je de 5 minuut chart bekijkt
posting datyum en tijd: " 25 mei 10, 16:33 "
meeste postings zijn van de dag zelf, cpst dus ook

range 1.00-1,10 vandaag
Ik gebruik IB

[verwijderd] 25 mei 2010 17:33

quote:
crackedtooth schreef:
Flatus: CPST vandaag gekocht 1.05, had je zelfs 2x de kans toe wanneer je de 5 minuut chart bekijkt
posting datyum en tijd: " 25 mei 10, 16:33 "
meeste postings zijn van de dag zelf, cpst dus ook

range 1.00-1,10 vandaag
Ik gebruik IB

Aha ik zie het,vergis mij in de datum excuses, dacht dat jouw posting van gister was, ik zit er in vanaf $1,03 als het lukt gaan ze voor $1,10 er weer uit.

[verwijderd] 25 mei 2010 21:27

CYCC lekker 2.16 +22 cent vandaag op bloedrode dag
2k teruggekocht 1.83

ANX 1.85 start positie, erg oversold

Bijlage:

[verwijderd] 26 mei 2010 13:33

Was leuk inkopen gister ben benieuwd naar vandaag.

[verwijderd] 26 mei 2010 17:45

LXRX 1.44 flat top triangle

Bijlage:

[verwijderd] 26 mei 2010 21:55

Kleine winstjes gelocked NIV , DDSS, ANX, CYCC

markten toch rood niet fijn

[verwijderd] 26 mei 2010 22:13

ALXA bezit er 3k van avg 3.13 en 10 2.5 dec 2.5 calls

Alexza Secures $25 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd. <ALXA.O>
pdf.reuters.com/pdfnews/pdfnews.asp?i...

MOUNTAIN VIEW, Calif., May 26 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq:
ALXA) announced today that it has obtained a committed equity financing facility under which it
may sell up to $25 million of its registered common stock to Azimuth Opportunity, Ltd. over a
24-month period. Alexza is not obligated to utilize any of the $25 million facility and remains
free to enter into and consummate other equity and debt financing transactions. This facility
replaces a similar facility that was established in March 2008 and expired after its 24-month
term.

"This flexible financing facility is an important component of our portfolio of financing options,
giving us the potential ability to raise capital quickly, at a competitive cost, and it may allow
us to manage dilution more effectively by issuing shares in multiple tranches at times of our
choosing over the next 24 months," said August J. Moretti, Senior Vice President and Chief
Financial Officer of Alexza. "We believe these advantages could benefit Alexza and our
stockholders as we continue to transition from the development stage to commercialization."

"This is an exciting time for Alexza. As our October 11, 2010 PDUFA goal date approaches, we
continue to scale-up our commercial manufacturing, and we are working with Biovail for the
expected launch of our lead program AZ-004 (Staccato loxapine) in Q1 2011," said Thomas B. King,
President and CEO of Alexza.

Alexza will determine, at its sole discretion, the timing, the dollar amount and the floor price
per share of each draw under this facility, subject to certain conditions. When and if Alexza
elects to use the facility, Alexza will issue shares to Azimuth at a small discount to the volume
weighted average price of Alexza's common stock over a preceding period of trading days. Reedland
Capital Partners, an Institutional Division of Financial West Group, Member FINRA/SIPC, will act
as placement agent and receive a fee for its services at the time of any draw under the facility.
Any shares sold under this facility will be sold pursuant to a shelf registration statement
declared effective by the Securities and Exchange Commission on May 20, 2010.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of any state.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and
commercialization of novel, proprietary products for the acute treatment of central nervous system
conditions. Alexza's technology, the Staccato system, vaporizes unformulated drug to form a
condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung
inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed
of therapeutic onset that is comparable to intravenous administration, but with greater ease,
patient comfort and convenience.

AZ-004 (Staccato loxapine) is Alexza's lead program and is being developed for the rapid
treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and
announced positive results from both of its AZ-004 Phase 3 clinical trials, submitted a New Drug
Application submission in December 2009, and has a Prescription Drug User Fee Act (PDUFA) goal
date of October 11, 2010. In February 2010, Alexza established a partnership with Biovail
Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize
AZ-004 in the U.S. and Canada.

Alexza has completed an end-of-Phase 2 meeting with the FDA for AZ-001 (Staccato
prochlorperazine) and has completed two Phase 2 studies with AZ-104 (Staccato loxapine,
low-dose). Both product candidates are being developed for the acute treatment of migraine
headache.

AZ-002 (Staccato alprazolam) has completed Phase 1 testing and one Phase 2a proof-of-concept
clinical trial. Product candidates that have completed Phase 1 testing are AZ-003 (Staccato
fentanyl) for the treatment of breakthrough pain, and AZ-007 (Staccato zaleplon) for the
treatment of insomnia. More information, including this and past press releases from Alexza, is
available online at www.alexza.com.

Safe Harbor Statement

This news release contains forward-looking statements that involve significant risks and
uncertainties. Any statement describing the Company's expectations or beliefs is a
forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and
should be considered an at-risk statement. Such statements are subject to certain risks and
uncertainties, particularly those inherent in the process of developing and commercializing drugs.
The Company's forward-looking statements also involve assumptions that, if they prove incorrect,
would cause its results to differ materially from those expressed or implied by such
forward-looking statements. These and other risks concerning Alexza's business are described in
additional detail in the Company's Annual Report on Form 10-K for the year ended December 31,
2009, and the Company's other Periodic and Current Reports filed with the Securities and Exchange
Commission. Forward-looking statements contained in this announcement are made as of this date,
and the Company undertakes no obligation to publicly update any forward-looking statement, whether
as a result of new information, future events or otherwise.

SOURCE Alexza Pharmaceuticals, Inc.

Thomas B. King, President and CEO, +1-650-944-7634, tking@alexza.com, or August J. Moretti, Senior
Vice President and CFO, +1-650-944-7788, amoretti@alexza.com, both of Alexza Pharmaceuticals,
Inc.

[verwijderd] 27 mei 2010 18:00

NIV 2.40 , lekkere bounce

ANX 1.90 lijkt toch goede support zone op sterk oversold

PKTX nog steeds interessant product (wel pinkie, protokinetix)

[verwijderd] 27 mei 2010 18:20

Ira Sohn hedge fund conferentie notes:
www.marketfolly.com/2010/05/ira-sohn-...

[verwijderd] 27 mei 2010 18:26

XIDE 4.25

Bijlage:

[verwijderd] 27 mei 2010 19:17

BCON .385 volume alert

5.451 Posts, Pagina: « 1 2 3 4 5 6 ... 36 37 38 39 40 41 42 43 44 45 46 ... 269 270 271 272 273 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 919,73 -6,18 -0,67% 10:58


Germany40^	22.471,90	-0,35%
BEL 20	4.414,11	-0,75%
Europe50^	5.441,29	-0,57%
US30^	43.334,30	+0,21%
Nasd100^	20.610,50	+0,29%
US500^	5.880,07	+0,32%
Japan225^	37.314,10	-0,72%
Gold spot	2.862,81	-0,38%
EUR/USD	1,0396	+0,00%
WTI	69,62	-0,74%